

CONTENTS

Section 1 : GENERAL PRINCIPLES IN DRUG THERAPY

1. Ethnopharmacology
2. Reverse pharmacology
3. Ecopharmacology
4. Translational pharmacology
5. Chronopharmacology
6. Spurious/falsely labelled/falsified/counterfeit medicines
7. Off-label use of drug
8. Orphan drug
9. Over-the-counter drugs
10. Generic drugs
11. Prodrugs
12. P-Drug concept
13. Rational use of drugs
14. Essential medicines – Indian context
15. Drug repositioning
16. Polypharmacy
17. Drug information centre
18. Pharmacoeconomic
19. Medication errors
20. Pharmacovigilance
21. Haemovigilance
22. Materiovigilance
23. Vaccine vigilance
24. Drug therapy in geriatric population
25. Drug therapy in paediatric population
26. Drug therapy in pregnancy and lactation
27. Isomerism
28. Structural activity relationship (SAR) of sympathomimetics
29. Structural activity relationship (SAR) of corticosteroids
30. Structural activity relationship (SAR) of antipsychotics

Section 2 : TECHNIQUES IN DRUG DISCOVERY

31. Bioinformatics
32. Proteomics
33. Metabolomics

Section 3 : DRUG DEVELOPMENT & CLINICAL TRIAL

34. Contract research organization (CRO)
35. Good clinical practice (GCP)

36. Clinical trial design
37. Vaccine trial
38. Controls in clinical trials
39. Placebo in clinical trials
40. Bias in clinical trials
41. Blinding in clinical trials
42. Methods of randomization
43. Randomized controlled trials
44. Recommended format for a research protocol
45. Phase 0 trials/microdosing studies
46. Phase 1 protocol design
47. Clinical trials – Phases
48. Highlights of new drugs and clinical trial rules 2019
49. Institutional ethics committee (IEC)
50. Non-inferiority, superiority and equivalence trial – concept
51. N-of-1 clinical trial designs
52. Platform, umbrella and basket trials
53. Schedule Y
54. Approach to drug discovery and development

Section 4 : NON-CLINICAL PHARMACOLOGY

55. Toxicological screening
56. Committee for the purpose of control & supervision of experiments on animals (CPCSEA)
57. Hybridoma technology
58. Knockout mouse
59. Transgenic animal
60. Nude mouse
61. Toxin in drug development
62. Alternate to animal models
63. Modified Langendorff technique

Section 5 : ANIMAL SCREENING METHODS

64. Models for screening of anti-diabetic drugs
65. Models for screening of anti-hypertensive drugs
66. Models for screening of anti-epileptic drugs
67. Models for screening of anti-psychotic drugs
68. Models for screening of anti-depressant drugs
69. Models for screening of anti-parkinson drugs
70. Models for screening of nootropic drugs
71. Models for screening of anti-anxiety drugs
72. Models for screening of anti-arrhythmic drugs
73. Models for screening of anti-anginal drugs
74. Models for screening of analgesic drugs
75. Models for screening of anti-inflammatory drugs

76. Models for screening of anti-ulcer drugs
77. Models for screening of muscle relaxant drugs
78. Models for screening of anti-fertility drugs
79. Models for screening of anti-cancer drugs
80. Models for screening of antioxidants

Section 6 : STATISTICS

81. Data
82. Central tendency
83. Standard deviation
84. Prevalence and incidence
85. The odds ratio and relative risk
86. Probability
87. Hypothesis testing
88. Type I & type II error
89. T Test
90. ANOVA
91. Chi square test
92. Parametric & nonparametric tests
93. Meta-analysis

Section 7 : ANALYTICAL BIOCHEMICAL ASSAYS

94. Enzyme-linked immunosorbent assay (ELISA)
95. Radioimmunoassay (RIA)
96. Fluorescence polarization immunoassay (FPIA)
97. Thin layer chromatography (TLC)
98. High-performance liquid chromatography (HPLC)
99. Polymerase chain reaction (PCR)
100. Mass spectrometry (MS)
101. Nuclear magnetic resonance (NMR)
102. High throughput screening (HTS)
103. Western blotting
104. Southern blotting
105. Spectrophotometry
106. Recombinant DNA technology
107. Limit tests in pharmaceuticals
108. Patch clamp technique
109. Therapeutic drug monitoring (TDM)

Section 8 : GENE AND DRUGS

110. Epigenetics
111. Pharmacogenetics and pharmacogenomics
112. Toxicogenomics

Section 9 : PHARMACOTHERAPY

- 113. Drugs for obesity
- 114. Drugs for rheumatoid arthritis
- 115. Drugs for inflammatory bowel disease
- 116. Mushroom poisoning
- 117. Myasthenia gravis
- 118. Recent advances in insulin therapy
- 119. Management of heart failure

Section 10 : HISTORY

- 120. Renowned scientists in pharmacology
- 121. History of antibiotic
- 122. History of general anaesthesia

Section 11 : MISCELLANEOUS

- 123. Prebiotics and probiotics
- 124. Role of a pharmacologist
- 125. Critical appraisal of a journal article
- 126. Cell culture
- 127. Check points in cell cycle

Section 12 : RECENT ADVANCES

- 128. Tyrosine kinase inhibitors in cancer therapy
- 129. Immunotoxins
- 130. Monoclonal antibodies
- 131. Biosimilar
- 132. Targeted drug delivery
- 133. Carrier based novel drug delivery system
- 134. Newly approved drugs – 2019
- 135. Newly approved drugs – 2018
- 136. Newly approved drugs – 2017
- 137. Newly approved drugs – 2016
- 138. Newly approved vaccines (2011–2019)
- 139. Me-too drugs
- 140. Medical burnout
- 141. Adaptive designs in clinical trials
- 142. Coronavirus disease (Covid-19)

Index